Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evoke Pharma Inc EVOK

Healthcare
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered... see more

Recent & Breaking News (NDAQ:EVOK)

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

GlobeNewswire October 28, 2024

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

GlobeNewswire October 23, 2024

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

GlobeNewswire October 22, 2024

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

GlobeNewswire October 1, 2024

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

GlobeNewswire September 19, 2024

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

GlobeNewswire September 9, 2024

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

GlobeNewswire August 13, 2024

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

GlobeNewswire August 8, 2024

Evoke Pharma, Inc. Announces Reverse Stock Split

GlobeNewswire July 30, 2024

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

GlobeNewswire June 17, 2024

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

GlobeNewswire May 16, 2024

Evoke Pharma Reports First Quarter 2024 Financial Results

GlobeNewswire May 14, 2024

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

GlobeNewswire April 17, 2024

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

GlobeNewswire March 21, 2024

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 14, 2024

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

GlobeNewswire March 7, 2024

Evoke Pharma Announces Closing of $7.5 Million Public Offering

GlobeNewswire February 14, 2024

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

GlobeNewswire February 9, 2024